Long Term Follow-up for RGX-202

Part of paid clinical trials in Little Rock, Arkansas.

Sponsor
REGENXBIO Inc.
Study ID
NCT06491927
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
MALE
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • No Intervention — GENETIC
    Observational study

Study Details

RGX-202-5101 is a long-term follow up study that evaluates the long-term safety and efficacy of RGX-202 in participants who have received RGX-202 (an investigative gene therapy designed to deliver a transgene for novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain) in a separate parent study.

Key Dates

Start date
May 8, 2024
Status verified
Mar 2026
Primary completion
Dec 1, 2029
Completion
Dec 1, 2029

Study Design

Enrollment
66 participants (estimated)

Arms

  • Arm: RGX-202 Recipients
    Subjects who have received RGX-202 in a separate parent study.

Primary Outcome Measure

Evaluation of long-term safety of RGX-202 [ Time Frame: Baseline, 5 years inclusive of parent study ]

Locations (5)

FacilityCityStateZIPSite coordinators
Arkansas Children's HospitalLittle RockArkansas72202-
Stanford School of Medicine /Division of Neuromuscular MedicinePalo AltoCalifornia94304-
Ann & Robert H. Lurie Children's Hospital of ChicagoChicagoIllinois60611-
The University of Texas Southwestern Medical CenterDallasTexas75390-
Virginia Commonwealth UniversityRichmondVirginia23298-

Find similar trials in Little Rock, AR

By condition
Duchenne muscular dystrophy
By specialty
Pediatrics
By research site
Arkansas Children's Hospital· Little Rock, ARStanford School of Medicine /Division of Neuromuscular Medicine· Palo Alto, CAAnn & Robert H. Lurie Children's Hospital of Chicago· Chicago, ILThe University of Texas Southwestern Medical Center· Dallas, TXVirginia Commonwealth University· Richmond, VA

Related Studies